Limited efficacy of gastrointestinal decontamination in severe slow-release carbamazepine overdose

Annals of Pharmacotherapy

Volumn 41, Issue 9, 2007, Pages 1539-1543

  Lurie, Yael ^a,b,c   Bentur, Yedidia ^a   Levy, Yishai ^b   Baum, Elena ^a   Krivoy, Norberto ^b  

^a Israel Poison Information Center

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c Israel Poison Information Center   (Israel)

Author keywords

Activated charcoal; Carbamazepine; Charcoal hemoperfusion; Overdose

Indexed keywords

ACTIVATED CARBON; ANTIBIOTIC AGENT; CARBAMAZEPINE; LITHIUM; PAROXETINE; RISPERIDONE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; ASPIRATION PNEUMONIA; BORDERLINE STATE; CASE REPORT; COMATOSE PATIENT; DRUG BLOOD LEVEL; DRUG OVERDOSE; HEMOPERFUSION; HUMAN; MALE; PRIORITY JOURNAL; REPEATED DRUG DOSE; SEIZURE; SEPSIS; SLOW RELEASE FORMULATION; SUICIDE ATTEMPT;

ADULT; ANTIDOTES; ANTIMANIC AGENTS; CARBAMAZEPINE; CHARCOAL; DECONTAMINATION; HUMANS; IRRIGATION; LOWER GASTROINTESTINAL TRACT; MALE; OVERDOSE; PERSONALITY DISORDERS; SUICIDE, ATTEMPTED;

EID: 34548180054     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K162     Document Type: Article

References (25)

1. Lai MW, Klein-Schwartz W, Rodgers GC, et al. 2005 Annual report of the American Association of Poison Control Centers' national poisoning and exposure database. Clin Toxicol 2006;44:803-932.
2. Package insert. Tegretol (carbamazepine) USP chewable tablets of 100 mg, tablets 200 mg, suspension 100 mg/5 ml, Tegretol-XR, carbamazepine extended-release tablets 100 mg, 200 mg, 400 mg. East Hanover, NJ: Novartis Pharmaceutical Corp., September 2006.
3. Deshpande G, Meert KL, Valentini RP. Repeat charcoal hemoperfusion treatments in life threatening carbamazepine overdose. Pediatr Nephrol 1999;13:775-7.
4. McNamara JO. Pharmacotherapy of epilepsies. In: Bruton LL, Lazo JS, Parker KL, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill, 2006:501-25.
5. Cameron RJ, Hungerford P, Dawson AH. Efficacy of charcoal hemoperfusion in massive carbamazepine poisoning. J Toxicol Clin Toxicol 2002;40:507-12.
6. Durelli L, Massazza U, Cavallo R. Carbamazepine toxicity and poisoning. Incidence, clinical features and management. Med Toxicol Adv Drug Exp 1989;4:95-107.
7. Doyone S. Anticonvulsants. In: Flomenbaum NE, Goldfrank LR, Hoffman RS, Howland MA, Lewin NA, Nelson LS, eds. Goldfrank's toxicological emergencies. 8th ed. New York: McGraw-Hill, 2006:731-45.
8. Braitberg G. Carbamazepine. In: Brent J, Wallace KL, Burkhart KK, Phillips SD, Donovan JW, eds. Critical care toxicology: diagnosis and management of critically poisoned patient. Philadelphia: Elsevier Mosby, 2005:559-64.
9. Leslie PJ, Heyworth R, Prescott LF. Cardiac complications of carbamazepine intoxication: treatment by haemoperfusion. Br Med J 1983;286:1018.
10. Hojer J, Malmlund HO, Berg A. Clinical features in 28 consecutive cases of laboratory confirmed massive poisoning with carbamazepine alone. J Toxicol Clin Toxicol 1993;31:449-58.
11. Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol 1999;37:731-51.
12. Position paper: whole bowel irrigation. J Toxicol Clin Toxicol 2004;42:843-54. Erratum in: J Toxicol Clin Toxicol 2004;42:1000.
13. Graudins A, Peden GD, Owsett RP. Massive overdose with controlled-release carbamazepine resulting in delayed peak serum concentrations and life-threatening toxicity. Emerg Med 2002;14:89-94.
14. Brahmi N, Kouraic N, Thabet H, Amamou M. Influence of activated charcoal on the pharmacokinetics and the clinical features of carbamazepine poisoning. Am J Emerg Med 2006;24:440-3.
15. Lapatto-Reiniluoto O, Kivisto KT, Neuvonen PJ. Activated charcoal alone and followed by whole-bowel irrigation in preventing the absorption of sustained-release drugs. Clin Pharmacol Ther 2001;70:255-60.
16. Chatty M, Sarkar P, Aggarwal A, Sakhuja V. Carbamazepine poisoning: treatment with haemodialysis. Nephrol Dial Transplant 2003;18:220-1.
17. Tapolyai M, Campbell M, Dailey K, Udvary-Nagy S. Hemodialysis is as effective as hemoperfusion for drug removal in carbamazepine poisoning. Nephron 2002;90:213-5.
18. Low CL, Haqqie SS, Desai RD, Bailie GR. Treatment of acute carbamazepine poisoning by hemoperfusion. Am J Emerg Med 1996;14:540-1.
19. Chan KM, Aguanno JJ, Jansen R, Dietzler DN. Charcoal hemoperfusion for treatment of carbamazepine poisoning. Clin Chem 1981;27:1300-2.
20. Nilsson C, Sterner G, Idvall J. Charcoal hemoperfusion for treatment of serious carbamazepine poisoning. Acta Med Scand 1984;216:137-40.
21. Adams BK, Mann MD, Aboo A, Isaacs S, Evans A. Prolonged gastric emptying half-time and gastric hypomotility after drug overdose. Am J Emerg Med 2004;22:548-54.
22. Shalkham AS, Kirrane BM, Hoffman RS, Goldfarb DS, Nelson LS. The availability and use of charcoal hemoperfusion in the treatment of poisoned patients. Am J Kidney Dis 2006;48:239-41.
23. Kielstein JT, Schwarz A, Arnavaz A, Sehlberg O, Emrich HM, Fliser D. High-flux hemodialysis - an effective alternative to hemoperfusion in the treatment of carbamazepine intoxication. Clin Nephrol 2002;57:484-6.
24. Yildiz TS, Toprak DG, Arisoy ES, Solak M, Toker K. Continuous venovenous hemodiafiltration to treat controlled-release carbamazepine overdose in a pediatric patient. Paediatr Anaesth 2006;16:1176-8.
25. Askenazi DJ, Goldstein SL, Chang IF, Elenberg E, Feig DI. Management of a severe carbamazepine overdose using albumin-enhanced continuous venovenous hemodialysis. Pediatrics 2004;113:406-9.